COMMUNIQUÉS West-GlobeNewswire

Interim report September 1, 2017 - May 31, 2018

28/06/2018 - 08:00

Company announcement no.11/2018 Report attached For further information, please contact: Martin Riise, Head of Investor Relations Tel: +45 53 39 22 50 Helle Rexen, Interim Head of Media Relations Tel: +45 20 74 28 40 [...]

ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 20th tranche of investment today

28/06/2018 - 07:18

Amsterdam, The Netherlands - 28 June 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 20 th Tranche of EUR 400,000 is issued as a private placement of 40 convertible notes (the "Notes [...]

Sanofi : Sanofi and Advent finalize negotiations for the acquisition of Zentiva

28/06/2018 - 07:01

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Advent finalize negotiations for the acquisition of Zentiva PARIS - June 28, 2018 - Sanofi and Advent International ("Advent") have finished [...]

Sanofi : Sanofi et Advent finalisent les négociations sur l'acquisition de Zentiva

28/06/2018 - 07:01

Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) Sanofi et Advent finalisent les négociations sur l'acquisition de Zentiva Paris - Le 28 juin 2018 - Sanofi et Advent International (« Advent ») [...]

argenx receives second preclinical milestone payment under its development agreement with AbbVie

28/06/2018 - 07:00

June 28, 2018 Breda, the Netherlands/Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]

Forty Seven Prices Initial Public Offering

28/06/2018 - 03:56

MENLO PARK, Calif., June 27, 2018 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical stage immuno-oncology company, announced today the pricing of its initial public offering of 7,035,000 shares of common [...]

Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018

27/06/2018 - 23:00

Patient enrollment in the two TRILOGY Phase 3 studies is progressing as planned: 463 patients enrolled and 41 patients randomized at 110 clinical sites as of June 26 th Phase 3 topline results tracking on schedule to be [...]

Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month

27/06/2018 - 22:31

Study reveals migraine causes significant disruption to daily life and work, which could be managed with better preventive treatments and workplace solutions Migraine is estimated to cost up to €27 billion in Europe and [...]

Imagin Medical Announces Uplisting to OTCQB

27/06/2018 - 22:30

VANCOUVER, British Columbia and BOSTON, June 27, 2018 (GLOBE NEWSWIRE) -- Imagin Medical (CSE:IME) (OTC PINK:IMEXF) (Frankfurt:DPD2) (Stuttgart:DPD2) (“Imagin” or the “Company”) is pleased to announce that its common [...]

Dr. Carrolee Barlow, M.D., Ph.D., Joins Supernus’ Board of Directors

27/06/2018 - 22:30

ROCKVILLE, Md., June 27, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]

Neos Therapeutics Appoints Jerry McLaughlin as Chief Executive Officer

27/06/2018 - 22:30

Mr. McLaughlin brings decades of operational and commercial biopharmaceutical industry experience DALLAS and FORT WORTH, Texas, June 27, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical [...]

AIT Therapeutics Announces Human and In-Vitro Nitric Oxide Data to be Presented at the 3rd Annual World Bronchiectasis Conference

27/06/2018 - 22:30

Two presentations to highlight the direct killing effect of nitric oxide and the use of the nitric oxide generator and delivery system as a potential therapy for Mycobacterium abscessus complex (MABSC) lung infection [...]

Edge Therapeutics Announces Updated Results from Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage

27/06/2018 - 22:30

Clinically meaningful benefit observed in NEWTON 2 primary endpoint in pre-specified WFNS 3 or 4 (severe) subgroup BERKELEY HEIGHTS, N.J., June 27, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today [...]

Inspire Medical Systems, Inc. Announces Regulatory Approval of Inspire Therapy for Treatment of Moderate to Severe Obstructive Sleep Apnea in Japan

27/06/2018 - 22:22

MINNEAPOLIS, June 27, 2018 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) ("Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive [...]

CohBar Completes Sale of $20 Million Under Controlled Equity Offering

27/06/2018 - 22:05

MENLO PARK, Calif., June 27, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), an innovative biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that [...]

TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007

27/06/2018 - 22:01

REGULATED INFORMATION PRESS RELEASE Transparency notification pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - June 27, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") [...]

VBL Therapeutics Announces Closing of $15.5 Million Registered Direct Offering

27/06/2018 - 22:01

TEL AVIV, Israel, June 27, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for [...]

Zafgen Announces Proposed Offering of Common Stock

27/06/2018 - 22:01

BOSTON, June 27, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by [...]

Kura Oncology Announces Commencement of Public Offering of Common Stock

27/06/2018 - 22:01

SAN DIEGO, June 27, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has [...]